Why the study?
Does continued neurohormonal blockade therapy improve survival and quality of life in patients with heart failure supported by left ventricular assist devices?
Does continued neurohormonal blockade therapy improve survival and quality of life in patients with heart failure supported by left ventricular assist devices?
Continued neurohormonal blockade therapy in patients with LVADs is associated with improved survival and quality of life, supporting the continuation of guideline-directed medical therapy in this population.
Answers are grounded in this paper and cite their sources.
Supports neurohormonal blockade continuation in LVAD patients; hypothesis-generating and requires randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McCullough et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: